Strs Ohio increased its position in Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 10.4% during the second quarter, according to its most recent filing with the SEC. The fund owned 560,109 shares of the biopharmaceutical company’s stock after buying an additional 52,710 shares during the period. Strs Ohio’s holdings in Alexion Pharmaceuticals were worth $65,398,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Pitcairn Co. boosted its stake in Alexion Pharmaceuticals by 32.5% in the second quarter. Pitcairn Co. now owns 20,654 shares of the biopharmaceutical company’s stock worth $2,412,000 after buying an additional 5,068 shares during the last quarter. Bank of Montreal Can acquired a new position in shares of Alexion Pharmaceuticals during the second quarter worth approximately $34,314,000. Daiwa Securities Group Inc. raised its position in shares of Alexion Pharmaceuticals by 3.8% in the second quarter. Daiwa Securities Group Inc. now owns 5,500 shares of the biopharmaceutical company’s stock worth $642,000 after buying an additional 200 shares during the period. Meeder Asset Management Inc. raised its position in shares of Alexion Pharmaceuticals by 651.0% in the second quarter. Meeder Asset Management Inc. now owns 6,121 shares of the biopharmaceutical company’s stock worth $715,000 after buying an additional 5,306 shares during the period. Finally, IBM Retirement Fund raised its position in shares of Alexion Pharmaceuticals by 1.2% in the second quarter. IBM Retirement Fund now owns 28,538 shares of the biopharmaceutical company’s stock worth $3,432,000 after buying an additional 335 shares during the period. 96.34% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded down 1.04% during midday trading on Wednesday, reaching $130.36. 1,210,394 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $131.16 and a 200-day moving average of $135.82. The stock has a market capitalization of $29.23 billion, a P/E ratio of 327.54 and a beta of 1.08. Alexion Pharmaceuticals Inc. has a 12-month low of $110.56 and a 12-month high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.17 by $0.04. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The company earned $753 million during the quarter, compared to analysts’ expectations of $743.18 million. During the same period in the prior year, the business posted $1.44 earnings per share. The company’s revenue for the quarter was up 18.4% on a year-over-year basis. Analysts anticipate that Alexion Pharmaceuticals Inc. will post $4.65 EPS for the current fiscal year.

ALXN has been the topic of a number of recent research reports. Jefferies Group reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a report on Sunday, May 29th. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 30th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $228.00 price target on shares of Alexion Pharmaceuticals in a report on Tuesday, May 31st. Vetr lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $171.50 price target on the stock. in a report on Thursday, June 2nd. Finally, Morgan Stanley reiterated an “overweight” rating and set a $189.00 price target (down previously from $203.00) on shares of Alexion Pharmaceuticals in a report on Tuesday, June 7th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. Alexion Pharmaceuticals has an average rating of “Buy” and a consensus price target of $182.85.

In other news, Director Leonard Bell sold 1,010 shares of the firm’s stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $137.14, for a total value of $138,511.40. Following the completion of the sale, the director now directly owns 405,289 shares of the company’s stock, valued at approximately $55,581,333.46. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Carsten Thiel sold 3,225 shares of the firm’s stock in a transaction dated Tuesday, September 13th. The stock was sold at an average price of $128.67, for a total transaction of $414,960.75. Following the completion of the sale, the executive vice president now directly owns 40,354 shares of the company’s stock, valued at $5,192,349.18. The disclosure for this sale can be found here. 4.41% of the stock is currently owned by insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals Inc. (NASDAQ:ALXN).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.